VIRAL HEPATITIS

Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan

T Imamura, O Yokosuka, T Kurihara, T Kanda, K Fukai, F Imazeki, H Saisho

Background: Although it has been reported that different hepatitis B virus (HBV) genotypes induce different clinical characteristics in patients with chronic liver diseases (CLD), there have been few reports that have detailed the distribution of HBV genotypes in acute forms of liver disease.

Methods: HBV genotypes were determined in 61 patients who had acute forms of liver disease (45 had acute self limited hepatitis (AH) and 16 had fulminant hepatitis (FH)) and in 531 patients with CLD, including 19 patients with severe acute exacerbation of CLD. We also analysed the enhancer II, core promoter, and precore region sequences for the presence of mutations.

Results: Expression of genotype B in patients with acute forms of liver disease was significantly greater than in those with CLD (39.3% vs 11.7%, respectively; p<0.001). Furthermore, expression of genotype B was significantly greater in patients with FH than in those with AH (62.5% vs 31.1%, respectively; p=0.027). The precore mutation A1896 and the core promoter mutation at nt 1753 and 1754 were found more frequently in FH than in AH, and genotype B was predominant in FH regardless of the presence of these mutations.

Conclusions: HBV genotype B was found more frequently in patients with acute forms of liver disease than in patients with CLD, and more frequently in patients with FH than in those with AH. These results suggest that this HBV genotype may induce more severe liver damage than other viral genotypes, at least in patients from Chiba, Japan.

Hepatitis B virus (HBV) is one of the major aetiological agents of acute and chronic liver diseases worldwide. HBV is classified into seven genotypes according to the phylogenetic analysis of its genomic sequences. The first four genotypes (genotypes A–D) were first described by Okamoto and colleagues. Six years later, two additional genotypes (genotypes E, F), and most recently genotype G, were described. The geographical distributions of these genotypes are different. Genotypes A and D were shown to be prevalent in Europe and the USA while genotypes E and F were found to be restricted to Africa and to be prevalent in Central and South America, respectively. Genotypes B and C were reported to be common in East Asia. In Japan, genotypes B and C were reported in 12% and 85%, respectively, of patients with chronic liver diseases (CLD). Recently, differences in the clinical features of CLD between individuals harbouring viruses of different genotypes were reported, with genotype A being shown to cause milder liver disease than genotype D. Orito et al also reported that patients with HBV of genotype C might undergo seroconversion at a later age than those with genotype B. Genotype C was reported to associate with more severe histological inflammation than genotype B. It has also been reported that in patients with chronic hepatitis, the response to interferon was lower in patients infected with genotype C than in those infected with genotype B. Thus the clinical course of acute liver diseases may also be different in patients with different viral genotypes. We therefore examined the distribution of HBV genotypes in patients who had an acute form of liver disease and compared it with the distribution seen in patients with CLD and acute exacerbation of CLD.

We previously showed that a G to A mutation at nt 1896 in the precore region (A1896), and mutations in the core region of HBV, were frequently found in fatal acute forms of liver disease. There have been a few reports that have described a relationship between precore mutations and fulminant hepatitis (FH). Similarly, Sato et al reported the presence of an A to T mutation at nt 1762 and a G to A mutation at nt 1764 in the core promoter region (T1762 and A1764) in Japanese patients with FH who did not manifest precore stop codon mutations. However, a study of patients from the USA and Europe failed to reveal such an association. We have also reported that mutations in the enhancer II/core promoter region of the virus were observed more frequently in patients with FH than in those with acute self limited hepatitis (AH) although the mutations in nucleotides 1762 and 1764 were not often seen. Thus the involvement of mutations in the core promoter and precore regions of HBV in the development of FH is still controversial and the relationship between these mutations and the different viral genotypes is not known. To examine the relation of these mutations to the different viral genotypes, we compared the HBV sequences in the core promoter and precore regions in each genotype.

Abbreviations: AH, acute self limited hepatitis; ALT, alanine aminotransferase; CLD, chronic liver diseases; ELSA, enzyme linked immunosorbant assay; FH, fulminant hepatitis; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus antibody; anti-HDV, hepatitis D virus antibody; PCR, polymerase chain reaction; A1896, G to A mutation at nt 1896 in the precore region; T1762 and A1764, A to T mutation at nt 1762 and G to A mutation at nt 1764 in the core promoter region; C/A/G 1753 and/or C/G1754, C/A/G to T mutation at nt 1753 and/or C/G to T mutation at nt 1754 in the core promoter region
MATERIALS AND METHODS

Patients

Sixty one patients with HBV related acute forms of liver disease that were consecutively admitted to Chiba University Hospital between 1980 and 2001 were examined in this study. They comprised 45 patients with AH and 16 with FH (table 1). HBV related acute forms of liver disease were diagnosed based on either the appearance of hepatitis B surface antigen (HBsAg) or the presence of >1 titre of immunoglobulin M (IgM) antibody to hepatitis B core antigen. Patients with a prolonged prothrombin time that was less than 40% of control values and who developed encephalopathy during the clinical course of their AH were diagnosed with FH. Patients who tested positive for HBsAg were considered to be HBV carriers, and those who had an abnormal alanine aminotransferase (ALT) level at some point during their observation period were diagnosed with CLD. CLD patients who had an elevated ALT of more than 600 IU/l, a total bilirubin of more than 3.0 mg/dl, or a prolonged prothrombin time of less than 50% of control values at any time during the clinical course of their disease were diagnosed with severe acute exacerbation of CLD. None of the patients with HBV related acute forms of liver disease or severe acute exacerbation of CLD tested positive for either anti-hepatitis C antibody (anti-HCV) or anti-hepatitis D antibody (anti-HDV). From the 590 patients with CLD who were inhaled to Chiba University Hospital (table 1), HBsAg, hepatitis B e antigen (HBeAg), and anti-HDV were determined using an enzyme linked immunosorbant assay (ELISA) (Abbot Laboratory, Chicago, Illinois, USA). Sequences were compared with the reported sequences of each genotype (genotype A, X04615; genotype B, X97851; genotype C, X70185; genotype D, X1954–1973). Briefly, 10 µl of DNA, extracted from the serum, were added to 5 µl of dNTP, 1 µl of Ex-Taq polymerase (Takara Syuzou, Kyoto, Japan), 5 µl of 10×Taq polymerase buffer, and 100 pmol of outer sense and antisense primers. The amplification profile was two minutes at 96 C, followed by 25 cycles at 96 C for one minute (denaturation), 55 C for one minute (annealing), and 72 C for one minute (extension). For the second PCR, 1 µl of the first PCR product was added to the same reaction buffer with inner sense and antisense primers except for the outer sense and antisense primers. The second PCR products were purified and sequenced using a Dye Terminator Kit (Applied Biosystems, Foster City, California, USA). Sequences were compared with the reported sequences of each genotype (genotype A, X04615; genotype B, X97851; genotype C, X04615).

Serological markers

HBsAg, hepatitis B e antigen (HBeAg), and anti-HDV were determined using an enzyme linked immunosorbant assay (ELISA) (Abbot Laboratory, Chicago, Illinois, USA). The presence of anti-HCV was also determined by ELISA (Ortho Diagnostics, Tokyo, Japan). Serum HBV DNA was quantified using an enzyme linked immunosorbant assay (ELISA) (Abbot Laboratory, Chicago, Illinois, USA). The HBV genotypes of the above CLD patients who had an elevated ALT of more than 600 IU/l, an abnormal alanine aminotransferase (ALT) level at some point during their observation period were diagnosed with CLD. None of the patients with HBV related acute forms of liver disease or severe acute exacerbation of CLD tested positive for either anti-hepatitis C antibody (anti-HCV) or anti-hepatitis D antibody (anti-HDV). From the 590 patients with CLD who were inhaled to Chiba University Hospital (table 1), HBsAg, hepatitis B e antigen (HBeAg), and anti-HDV were determined using an enzyme linked immunosorbant assay (ELISA) (Abbot Laboratory, Chicago, Illinois, USA). Sequences were compared with the reported sequences of each genotype (genotype A, X04615; genotype B, X97851; genotype C, X04615).

RESULTS

Characteristics of patients whose HBV genotypes were investigated

Table 1 shows the clinical and laboratory data of the patients whose HBV genotypes were investigated. There were no statistically significant differences in mean age or sex between patients with AH, FH, CLD, and acute exacerbation of CLD. The percentage of FH patients who were positive for HBeAg was significantly lower than that seen in patients with AH (25.0% v 65.2%; p<0.001). Mean HBV DNA levels

<table>
<thead>
<tr>
<th>Case</th>
<th>No studied</th>
<th>Sex (M:F)</th>
<th>Age (y)</th>
<th>ALT (U/l)</th>
<th>HBeAg positivity (%)</th>
<th>HBV DNA (log copies/ml)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute forms of liver disease</td>
<td>61</td>
<td>41:20</td>
<td>34.1 (11.1)</td>
<td>3143 (3251)</td>
<td>54.1*</td>
<td>4.58 (1.31)*</td>
</tr>
<tr>
<td>(AH)</td>
<td>45</td>
<td>29:16</td>
<td>37.1 (12.5)</td>
<td>3092 (2870)</td>
<td>65.2*</td>
<td>4.48 (1.26)*</td>
</tr>
<tr>
<td>(FH)</td>
<td>16</td>
<td>12.4</td>
<td>43.0 (9.20)</td>
<td>2959 (4068)</td>
<td>25.0*</td>
<td>4.71 (1.40)*</td>
</tr>
<tr>
<td>CLD</td>
<td>531</td>
<td>360:171</td>
<td>38.5 (13.9)</td>
<td>113.4 (1273)</td>
<td>58.7*</td>
<td>6.19 (1.69)*</td>
</tr>
<tr>
<td>Total</td>
<td>592</td>
<td>401:191</td>
<td>38.3 (13.7)</td>
<td>370.8 (1238.1)</td>
<td>57.9</td>
<td>5.97 (1.51)*</td>
</tr>
</tbody>
</table>

*Values are mean (SD). **p<0.001; NS, NS

AH, acute self limited hepatitis; ALT, alanine aminotransferase; CLD, chronic liver diseases; FH, fulminant hepatitis; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

(AH and FH are included in acute forms of liver disease.)

(Acute exacerbation of CLD is included in CLD.)

Genotypes were also examined by the method of Mizokami et al in cases where the ELISA results were inconclusive. Briefly, S-gene sequences that were amplified by semi nested PCR were digested with restriction endonucleases, and the genotypes were determined by the restriction fragment length polymorphisms of the digested PCR products. Our results from the use of either of the above techniques were comparable.
were significantly lower in patients who had an acute form of liver disease than in those with CLD (4.58 (1.31) v 6.19 (1.65) log copies/ml; p, 0.001), although they were comparable in patients with AH and FH (4.48 (1.26) v 4.71 (1.40) log copies/ml; NS) and in patients with CLD and acute exacerbation of CLD (6.19 (1.65) v 5.91 (1.74) log copies/ml; NS).

**Distribution of HBV genotypes in patients with an acute form of liver disease or CLD**

The distribution of HBV genotypes in the various forms of liver disease is shown in table 2. Among the 61 patients who had an acute form of liver disease, six (9.8%), 24 (39.3%), and 31 (50.8%) patients were positive for viral genotype A, genotype B, and genotype C, respectively. Genotype B was found significantly more often in patients with an acute form of liver disease than in patients with CLD (24/61 (39.3%) v 62/531 (11.7%); p, 0.001). There was no difference in the frequency of genotype B between patients with CLD and those with acute exacerbation of CLD (62/531 (11.7%) v 4/19 (21.1%); NS). Genotype B tended to be found more often in patients with FH than in patients with AH (10/16 (62.5%) v 14/45 (31.3%); p = 0.027).

**Precore region (nt1896) mutation in HBV genotypes**

Of the 69 patients whose HBV sequences were investigated, five contained virus with genotype A, 27 contained virus with genotype B, and 37 contained virus with genotype C. The nucleotide sequences of the enhancer II, core promoter, and precore regions in each genotype are shown in fig 1. Regarding mutations in the precore region, the number of patients with A1896 is shown in table 3. A1896 was found more frequently in patients with FH than in patients with AH (p<0.001). The percentages of patients with A1896 in genotypes B and C were comparable (11/27 (40.7%) v 10/37 (42.3%); NS). In patients with FH, the distributions of HBV genotypes A, B, and C with and without A1896 were 0, 7, 4 and 1, 3, 0, respectively; hence the percentages of genotype B patients who either had or did not have this mutation were

---

### Table 2 Distribution of HBV genotypes in various forms of hepatitis B

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>No studied</th>
<th>Genotype A</th>
<th>Genotype B</th>
<th>Genotype C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute forms of liver disease</td>
<td>61</td>
<td>6 (9.8%)</td>
<td>24 (39.3%)</td>
<td>31 (50.8%)</td>
</tr>
<tr>
<td>(AH)</td>
<td>45</td>
<td>5 (11.1%)</td>
<td>14 (31.1%)</td>
<td>26 (57.8%)</td>
</tr>
<tr>
<td>(FH)</td>
<td>16</td>
<td>1 (6.2%)</td>
<td>10 (62.5%)</td>
<td>5 (31.3%)</td>
</tr>
<tr>
<td>CLD</td>
<td>531</td>
<td>10 (1.9%)</td>
<td>62 (11.7%)</td>
<td>459 (86.4%)</td>
</tr>
<tr>
<td>(Acute exacerbation of CLD)</td>
<td>19</td>
<td>2 (10.5%)</td>
<td>4 (21.1%)</td>
<td>13 (68.4%)</td>
</tr>
<tr>
<td>Total</td>
<td>592</td>
<td>16</td>
<td>86</td>
<td>490</td>
</tr>
</tbody>
</table>

* p<0.001; b p=0.027; NS.

**The number of patients with and without HBV genotype B was compared between disease groups.**

**HBV, hepatitis B virus; AH, acute self limited hepatitis; CLD, chronic liver diseases; FH, fulminant hepatitis.**

(AH and FH are included in acute forms of liver disease.)

(Acute exacerbation of CLD is included in CLD.)

---

### Table 3 Mutations in the precore region (nt 1896) in each genotype

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Genotype A</th>
<th>Genotype B</th>
<th>Genotype C</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>AH</td>
<td>0/4 (0%)</td>
<td>0/13 (0%)</td>
<td>0/20 (0%)</td>
<td>0/37 (0%)</td>
</tr>
<tr>
<td>FH</td>
<td>0/1 (0%)</td>
<td>7/10 (70.0%)</td>
<td>4/100 (0.0%)</td>
<td>11/15 (73.3%)</td>
</tr>
<tr>
<td>Acute exacerbation of CLD</td>
<td>0/0 (0%)</td>
<td>4/1 (100%)</td>
<td>6/13 (46.2%)</td>
<td>10/17 (55.6%)</td>
</tr>
<tr>
<td>Total</td>
<td>0/5 (0%)</td>
<td>11/27 (40.7%)</td>
<td>10/37 (42.3%)</td>
<td>21/69 (32.8%)</td>
</tr>
</tbody>
</table>

* p<0.001; NS.

AH, acute self limited hepatitis; FH, fulminant hepatitis; CLD, chronic liver disease.

---

### Table 4 Mutations in the core promoter region (nt1762 and 1764) in each genotype

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Genotype A</th>
<th>Genotype B</th>
<th>Genotype C</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>AH</td>
<td>0/4 (0%)</td>
<td>1/13 (8.3%)</td>
<td>6/20 (30.0%)</td>
<td>7/37 (18.9%)</td>
</tr>
<tr>
<td>FH</td>
<td>1/1 (100%)</td>
<td>2/10 (20.0%)</td>
<td>2/4 (50.0%)</td>
<td>5/15 (33.3%)</td>
</tr>
<tr>
<td>Acute exacerbation of CLD</td>
<td>0/0 (0%)</td>
<td>0/4 (0%)</td>
<td>8/13 (61.5%)</td>
<td>8/17 (47.1%)</td>
</tr>
<tr>
<td>Total</td>
<td>1/5 (20.0%)</td>
<td>3/27 (11.1%)</td>
<td>16/37 (43.2%)</td>
<td>20/69 (29.0%)</td>
</tr>
</tbody>
</table>

* NS; b p=0.005.

AH, acute self limited hepatitis; FH, fulminant hepatitis; CLD, chronic liver diseases.

---

### Table 5 Mutations in the core promoter region (nt1753 and 1754) in each genotype

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Genotype A</th>
<th>Genotype B</th>
<th>Genotype C</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>AH</td>
<td>0/4 (0%)</td>
<td>2/13 (15.4%)</td>
<td>2/20 (10.0%)</td>
<td>4/37 (10.8%)</td>
</tr>
<tr>
<td>FH</td>
<td>1/1 (100%)</td>
<td>4/10 (40.0%)</td>
<td>2/4 (50.0%)</td>
<td>7/15 (46.7%)</td>
</tr>
<tr>
<td>Acute exacerbation of CLD</td>
<td>0/0 (0%)</td>
<td>3/4 (75.0%)</td>
<td>5/13 (38.5%)</td>
<td>8/17 (47.1%)</td>
</tr>
<tr>
<td>Total</td>
<td>1/5 (20.0%)</td>
<td>9/27 (33.3%)</td>
<td>9/37 (18.9%)</td>
<td>19/69 (27.5%)</td>
</tr>
</tbody>
</table>

* p=0.004; NS.
comparable (7/11 (63.6%) v 3/4 (75%); NS). Thus genotype B tended to be predominant in FH, independent of the presence or absence of A1896. No patient carrying genotype A had A1896 although the number of patients with genotype A was very small. For this reason, comparisons were only made between genotypes B or C.

Mutations in the core promoter region (nt 1762 and 1764/nt 1753 and 1754) of the different HBV genotypes

We compared our core promoter mutation data with previously reported HBV sequences. Mutations at nt 1762 and 1764 and nt 1753 and 1754 were found when they were
compared with each respective prototype sequence. These were all located in AT rich regions of the prototype sequences in the core promoter region. The numbers of patients with T1762 and A1764 are shown in table 4. There was no difference in the frequency of these mutations between patients with FH and those with AH (5/15 (33.3%) vs 7/37 (18.9%); NS). T1762 and A1764 tended to be seen more frequently in patients with genotype C than in those with genotype B (16/37 (43.2%) vs 3/27 (11.1%); p = 0.005). The numbers of patients with C/A/G 1753 and/or C/G1754 are shown in table 5. These mutations were found more frequently in patients with FH than in patients with AH (7/15 (46.7%) vs 4/37 (10.8%); p = 0.004). The percentages of patients with these mutations in genotypes B and C were comparable (9/27 (33.3%) vs 9/37 (18.9%); NS). In patients with FH, the distributions of HBV genotypes A, B, and C with and without these mutations were 1, 4, 2 and 0, 6, 2 respectively; hence the percentages of genotype B patients

<table>
<thead>
<tr>
<th>Genotype</th>
<th>X70183</th>
<th>GenotypeB</th>
<th>X79853</th>
<th>GenotypeC</th>
<th>X04615</th>
</tr>
</thead>
<tbody>
<tr>
<td>AH1</td>
<td>A</td>
<td>TATTAGGAGG</td>
<td>TCTAGGCAT</td>
<td>AAATTGTCCT</td>
<td>TTTAGCTTG</td>
</tr>
<tr>
<td>AH2</td>
<td>A</td>
<td>TATTAGGAGG</td>
<td>TCTAGGCAT</td>
<td>AAATTGTCCT</td>
<td>TTTAGCTTG</td>
</tr>
<tr>
<td>AH3</td>
<td>A</td>
<td>TATTAGGAGG</td>
<td>TCTAGGCAT</td>
<td>AAATTGTCCT</td>
<td>TTTAGCTTG</td>
</tr>
<tr>
<td>AH4</td>
<td>T</td>
<td>TATTAGGAGG</td>
<td>TCTAGGCAT</td>
<td>AAATTGTCCT</td>
<td>TTTAGCTTG</td>
</tr>
<tr>
<td>FH1</td>
<td>T</td>
<td>TATTAGGAGG</td>
<td>TCTAGGCAT</td>
<td>AAATTGTCCT</td>
<td>TTTAGCTTG</td>
</tr>
</tbody>
</table>

Figure 1 Continued.
who either had or did not have these mutations were comparable (4/7 (57.1%) v 6/8 (75.0%); NS). Thus genotype B tended to predominate in FH independent of the presence or absence of these mutations.

**DISCUSSION**

Our results showed that genotypes B and C of HBV were present in about 40% and 50%, respectively, of patients with an acute form of liver disease. In contrast, genotype C was found in 86% of patients with CLD and 68.4% of patients with acute exacerbation of CLD, suggesting that the distribution of HBV genotype B in acute forms of liver disease was higher than that seen in chronic forms of the disease. Interestingly, the distribution of genotype B was higher in patients with FH than in patients with AH, suggesting a stronger association of genotype B with more severe acute forms of liver disease.

Acute hepatitis B is thought to be transmitted horizontally. As such, our results might reflect the distribution of HBV genotypes in the general population. The distribution of HBV genotypes in patients with an acute form of liver disease suggests that individuals with genotype B are more prevalent in the general population—that is, the prevalence of HBV...
genotype B might be higher in the general population than in patients with CLD. Fujie et al. reported a higher incidence of genotype B in asymptomatic carrier patients who were positive for antibody to hepatitis B e antigen (43.2%) than in patients with hepatocellular carcinoma who were positive for antibody to hepatitis B e antigen (5.9%), although these authors did not compare the prevalence of genotypes B and C in chronic liver diseases. Another reason for the higher distribution of genotype B in acute forms of liver disease might be that the percentage of clinical HBV infection compared with subclinical infection might be higher in patients infected with genotype B than in those with genotype C. Kozik et al. reported that the ratio of clinical and subclinical HBV infection was 1:30 in Thai children, although they did not compare the ratio between HBV genotypes.

From our results that showed that genotype B was more prevalent in patients with FH than AH, we speculate that genotype B of HBV may induce more liver damage than genotype C.

Currently, we do not know why genotype B viruses might cause more liver damage than genotype C viruses. As HBV is not a cytotoxic virus, hepatocyte death is caused by the immune response of the host to the viral infection. Therefore, the ability of these viruses to replicate themselves, and/or differences in their amino acid sequences that bind to hepatocyte HLA class I molecules, the target of peptide specific CTL responses probably play a role.

Genotype B virus may have the motifs that strongly bind to HLA A1896 could not occur in HBV genotype A (with T at nt 1858) including the patient with FH. It has been speculated that variations of transcription factors to the core promoter region, as well as core promoter and as such may change the binding efficiency of these factors. From our results that showed that genotype B was more prevalent in patients with FH than AH, we speculate that genotype B of HBV may induce more liver damage than genotype C.

ACKNOWLEDGEMENTS

We thank Dr M Shima of the Department of Public Health at the Graduate School of Medicine at Chiba University for his kind advice concerning the statistical analyses that were carried out in this study.

Authors’ affiliations

T Imamura, O Yokosuka, T Kurihara, T Kanda, K Fukui, F Imazeki, H Saisho, Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Japan

REFERENCES


Distribution of hepatitis B viral genotypes

Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan
T Imamura, O Yokosuka, T Kurihara, T Kanda, K Fukai, F Imazeki and H Saisho

Gut 2003 52: 1630-1637
doi: 10.1136/gut.52.11.1630

Updated information and services can be found at:
http://gut.bmj.com/content/52/11/1630

These include:

References
This article cites 42 articles, 12 of which you can access for free at:
http://gut.bmj.com/content/52/11/1630#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/